Compounds > pirfenidone
Page last updated: 2024-08-23

pirfenidone and gemcitabine

pirfenidone has been researched along with gemcitabine in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Cui, L; Eguchi, D; Fujiwara, K; Ikenaga, N; Kozono, S; Mizumoto, K; Ohuchida, K; Tanaka, M1
Cai, R; Hao, J; Ji, T; Lang, J; Nie, G; Qi, F; Qin, Z; Wang, J; Wu, W; Zhang, L; Zhang, Y; Zhao, X; Zhao, Y1
Bai, Y; Du, L; Gao, F; Jin, L; Li, F; Lin, L; Niu, S; Shi, Q; Sun, T; Wu, J; Zhu, LM1
Caires, HR; Castro, I; Cavadas, B; Ferreira, D; Oliveira, MJ; Pereira, L; Santos, LL; Vasconcelos, MH; Xavier, CPR1

Other Studies

4 other study(ies) available for pirfenidone and gemcitabine

ArticleYear
Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells.
    Cancer research, 2013, Apr-01, Volume: 73, Issue:7

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Deoxycytidine; Female; Fibrosis; Gemcitabine; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Pancreatic Stellate Cells; Platelet-Derived Growth Factor; Pyridones; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stromal Cells; Tumor Cells, Cultured

2013
Designing Liposomes To Suppress Extracellular Matrix Expression To Enhance Drug Penetration and Pancreatic Tumor Therapy.
    ACS nano, 2017, 09-26, Volume: 11, Issue:9

    Topics: Animals; Antineoplastic Agents; Deoxycytidine; Extracellular Matrix; Gemcitabine; Humans; Liposomes; Matrix Metalloproteinase 2; Mice, Nude; Pancreatic Neoplasms; Pancreatic Stellate Cells; Peptides; Pyridones; Tumor Cells, Cultured

2017
Biodegradable, pH-Sensitive Hollow Mesoporous Organosilica Nanoparticle (HMON) with Controlled Release of Pirfenidone and Ultrasound-Target-Microbubble-Destruction (UTMD) for Pancreatic Cancer Treatment.
    Theranostics, 2019, Volume: 9, Issue:20

    Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Carriers; Extracellular Matrix; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Hydrogen-Ion Concentration; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microbubbles; Nanoparticles; Pancreatic Neoplasms; Pyridones; Silicon Dioxide

2019
Chitinase 3-like-1 and fibronectin in the cargo of extracellular vesicles shed by human macrophages influence pancreatic cancer cellular response to gemcitabine.
    Cancer letters, 2021, 03-31, Volume: 501

    Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chitinase-3-Like Protein 1; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Vesicles; Fibronectins; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Macrophages; Pancreatic Neoplasms; Pentoxifylline; Proteomics; Pyridones; Survival Analysis; Up-Regulation

2021